Curis Inc., a biotechnology company specializing in the development of emavusertib, has announced a significant financial move involving a registered direct offering and a concurrent private placement. The company has entered into an agreement with both existing and new investors to purchase 1,538,460 shares of its common stock. Additionally, Curis will issue unregistered pre-funded warrants to acquire up to 1,538,461 shares of common stock at a nominal exercise price and unregistered warrants to purchase up to 3,076,921 shares at an exercise price of $2.15 per share. The private placement is set at a combined purchase price of $2.275 for one share and the associated warrant, and $2.265 for one pre-funded warrant and the associated warrant. This strategic financial arrangement aims to bolster Curis's capital as it continues to focus on the advancement of its IRAK4 inhibitor, emavusertib.